Status:
TERMINATED
SUV on PSMA PET/CT in Non-Prostate Tumors
Lead Sponsor:
Sir Mortimer B. Davis - Jewish General Hospital
Conditions:
Cancer
Eligibility:
All Genders
18-120 years
Phase:
PHASE2
Brief Summary
The objective of this pilot study is to evaluate if 18F-DCFPyL PET/CT or 68Ga-PSMA-11 PET/CT can be used for detection and staging of PSMA-expressing non-prostate tumor.
Detailed Description
Prostate specific membrane antigen (PSMA) is a unique membrane bound glycoprotein, which is over-expressed many fold on prostate cancer cells and other types of cancer. Since PSMA is a new target for ...
Eligibility Criteria
Inclusion
- Age 18 years or older, able to understand and provide written informed consent
- The patient has a tumor known or suspected to have PSMA expression, as reported in the literature or by positive histopathological staining for PSMA.
- The known or suspected tumor must fall into one of the following categories: carcinoma, sarcoma, or hematologic cancer.
- ECOG performance status 0 - 3, inclusive
- Under referring physician's care
- Able to tolerate the physical/logistical requirements of a PET/CT scan including lying supine for up to 40 minutes with the arms above the head and tolerating intravenous cannulation
Exclusion
- Patients with neoplasm known in literature to not have PSMA expression, unless patient specific tissue sampling shows PSMA staining on histopathology.
- Medically unstable patients (e.g. acute cardiac or respiratory distress or hypotensive, etc.)
- Patients who exceed the safe weight limit of the PET/CT bed (200 kg) or who cannot fit through the PET/CT bore (70 cm diameter)
- Patients with unmanageable claustrophobia
- Pregnancy
Key Trial Info
Start Date :
July 25 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2023
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT03841760
Start Date
July 25 2019
End Date
April 1 2023
Last Update
April 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jewish General Hospital
Montreal, Quebec, Canada, H3T1E2